Ashibio Inc

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2/3
Matrix metalloproteinase 9 (MMP-9) · Matrix metalloproteinase-9 (MMP-9)Monoclonal antibody
Fibrodysplasia Ossificans Progressiva

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
December 2028 (1)
AndecaliximabPhase 1/2Heterotopic Ossification (HO)
Est. primary completion 2028-12 · NCT07024407 · CT.gov ↗
What to watch
2029 (1)
February 2029 (1)
AndecaliximabPhase 2/3Fibrodysplasia Ossificans Progressiva
Est. primary completion 2029-02-04 · NCT06508021 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.